4-Ethylpiperazine-1-carboximidamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4-Ethylpiperazine-1-carboximidamide
• 化学式: C₇H₁₆N₄
• mdl: MFCD06594357
• 分子量: 156.231
• InChiKey: GOHSBAJKFRIIOK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  56.4
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-Ethylpiperazine-1-carboximidamide 、 methyl 3-oxo-3-(6,8,8,9-tetramethyl-2-oxo-8,9-dihydro-2H-pyrano[3,2-g]quinolin-3-yl)propanoate 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 以67%的产率得到3-[2-(4-ethylpiperazin-1-yl)-6-oxo-1,6-dihydropyrimidin-4-yl]-6,8,8,9-tetramethyl-8,9-dihydro-2H-pyrano[3,2-g]quinolin-2-one
  参考文献：
  名称：

  Synthesis of 2H-pyrano[3,2-g]quinolin-2-ones containing a pyrimidinone moiety and characterization of their anticoagulant activity via inhibition of blood coagulation factors Xa and XIa

  摘要：

  7-羟基-1,2,2,4-四甲基氢醌-6-甲醛与甲基3-氧代戊二酸的反应被用于合成了一系列在吡啶环上具有不同程度氢化的3-氧代-3-(6,8,8,9-四甲基-2-氧代-2H-吡喃并[3,2-g]喹啉-3-基)丙酸酯，这些化合物与羧基咪唑胺的缩合反应提供了一系列新的6,8,8,9-四甲基-3-(6-氧代-1,6-二氢嘧啶-4-基)-2H-吡喃并[3,2-g]喹啉-2-酮。研究发现，这类化合物中有一些表现出对血液凝固因子Xа和XIa相对较高的抑制活性。

  DOI：

  10.1007/s10593-021-02945-z

文献信息

• [EN] PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS<br/>[FR] PYRIMIDINE CARBOXAMIDES À TITRE DE BLOQUEURS DES CANAUX SODIQUES
  申请人：PURDUE PHARMA LP

  公开号：WO2014135955A1

  公开（公告）日：2014-09-12

  The present disclosure provides substituted pyrimidine carboxamides of Formula (I) and the pharmaceutically acceptable salts and solvates thereof, wherein A1, X, A2, W1, W2, W3, E, Z, and R4 are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of sodium channels. Compounds of the present disclosure are especially useful for treating pain.

  本公开提供了公式（I）的取代嘧啶羧酰胺及其在药学上可接受的盐和溶剂化合物，其中A1、X、A2、W1、W2、W3、E、Z和R4的定义如规范中所述。本公开还涉及使用公式（I）的化合物治疗对钠通道阻断有反应的疾病。本公开的化合物特别适用于治疗疼痛。
• FACTOR XA INHIBITORS
  申请人：Zhu Bing-Yan

  公开号：US20120178733A1

  公开（公告）日：2012-07-12

  The present invention is directed to compounds represented by Formula I and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof which are inhibitors of Factor Xa. The present invention is also directed to and intermediates used in making such compounds, pharmaceutical compositions containing such compounds, methods to prevent or treat a number of conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample.

  本发明涉及由I式表示的化合物及其药学上可接受的盐、溶剂、水合物和前药，这些化合物是Xa因子的抑制剂。本发明还涉及用于制备这些化合物的中间体，含有这些化合物的药物组合物，预防或治疗由不良血栓形成引起的多种情况的方法，以及抑制血样的凝血方法。
• AMINO ACID LIPIDS AND USES THEREOF
  申请人：Marina Biotech, Inc.

  公开号：US20140037714A1

  公开（公告）日：2014-02-06

  This disclosure provides a range of amino acid lipid compounds and compositions useful for drug delivery, therapeutics, and the diagnosis and treatment of diseases and conditions. The amino acid lipid compounds and compositions can be used for delivery of various agents such as nucleic acid therapeutics to cells, tissues, organs, and subjects.

  本公开提供了一系列氨基酸脂质化合物和组合物，可用于药物传递、治疗以及疾病和病症的诊断和治疗。氨基酸脂质化合物和组合物可用于向细胞、组织、器官和受试者传递各种药物，例如核酸治疗药物。
• TYROSINE-BASED LIPIDS FOR DELIVERY OF THERAPEUTICS
  申请人：Marina Biotech, Inc.

  公开号：US20160206739A1

  公开（公告）日：2016-07-21

  This disclosure provides a range of tyrosine amino acid lipid compounds and compositions useful for drug delivery, therapeutics, and the diagnosis and treatment of diseases and conditions. The amino acid lipid compounds and compositions can be used for delivery of various agents such as nucleic acid therapeutics to cells, tissues, organs, and subjects.

  本披露提供了一系列酪氨酸氨基酸脂类化合物和组合物，可用于药物输送、治疗以及疾病和病症的诊断和治疗。这些氨基酸脂类化合物和组合物可用于将各种药剂如核酸治疗剂输送至细胞、组织、器官和受试者。
• Pharmacologically active CNS compound
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：EP0459819A2

  公开（公告）日：1991-12-04

  The invention provides a series of compounds of formula (I) and salts thereof, wherein for example, R¹ and R², which may be the same or different each represent -NR¹³R¹⁴ where R¹³ and R¹⁴ may each independently represent hydrogen or alkyl or, taken together with the nitrogen atom to which they are attached form a heterocyclic ring, optionally substituted by one or more alkyl or arylalkyl groups and optionally containing a further heteroatom; R³ is hydrogen, haloalkyl, alkoxymethyl or alkyl; R⁴ is hydrogen, nitro or halo; R⁵ is hydrogen or halo; R⁶ is hydrogen, halo, nitro, amino, alkylamino or dialkylamino; R⁷ is hydrogen or halo; R⁸ is hydrogen or halo; The compounds may be used for the treatment or prophylaxis of a neurodegenerative or other neurological disorder of the CNS, the aetiology or which includes excessive release of the neurotransmitter glutamate.

  本发明提供了一系列式 (I) 的化合物 及其盐类，其中例如 R¹和R²可以相同或不同，各自代表-NR¹³R¹⁴，其中R¹³和R¹⁴可以各自独立地代表氢或烷基，或与它们所连接的氮原子一起形成杂环，任选被一个或多个烷基或芳烷基取代，并任选含有另一个杂原子； R³ 是氢、卤代烷基、烷氧基甲基或烷基； R⁴ 是氢、硝基或卤代； R⁵ 是氢或卤素； R⁶ 是氢、卤素、硝基、氨基、烷基氨基或二烷基氨基； R⁷ 是氢或卤素； R⁸ 是氢或卤素； 这些化合物可用于治疗或预防中枢神经系统的神经退行性疾病或其他神经疾病，其病因或包括神经递质谷氨酸的过度释放。